Buy LLY by Apr 16, 2026.

Reason 1.) Wegovy pill's 16.6% weight loss has to be taken into context. That number comes from the OASIS-4 trial which only had 307 patients, 79% were female, and 92% were white. By comparison, the ATTAIN-1 trial for orforglipron had 3127 patients, 64% female, and 57% white. In orfo's phase 2 they achieved 13.5% weight loss at 36 weeks. That study had 272 patients, 59% female, 91% white. There is increasing data that suggests females and whites respond better to …